新型冠状病毒肺炎(COVID-19)临床诊断病例的随访研究

注册号:

Registration number:

ChiCTR2000033186 

最近更新日期:

Date of Last Refreshed on:

2021-04-23 01:32:08 

注册时间:

Date of Registration:

2020-05-23 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

新型冠状病毒肺炎(COVID-19)临床诊断病例的随访研究

Public title:

A follow-up study about clinically diagnosed cases of novel coronavirus pneumonia (COVID-19)

注册题目简写:

English Acronym:

研究课题的正式科学名称:

新型冠状病毒肺炎(COVID-19)临床诊断病例的随访研究

Scientific title:

A follow-up study about clinically diagnosed cases of novel coronavirus pneumonia (COVID-19)

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

安晓彩 

研究负责人:

许爱国 

Applicant:

An Xiaocai 

Study leader:

Xu Aiguo 

申请注册联系人电话:

Applicant telephone:

+86 15638829101

研究负责人电话:

Study leader's
telephone:

+86 13523510886

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1186417101@qq.com

研究负责人电子邮件:

Study leader's E-mail:

aiguoxu@hotmail.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

河南省郑州市二七区建设东路1号

研究负责人通讯地址:

河南省郑州市二七区建设东路1号

Applicant address:

1 Jianshe Road East, Zhengzhou, He'nan, China

Study leader's address:

1 Jianshe Road East, Erqi District, Zhengzhou, He'nan, China

申请注册联系人邮政编码:

Applicant postcode:

450000

研究负责人邮政编码:

Study leader's postcode:

450000

申请人所在单位:

郑州大学第一附属医院

Applicant's institution:

The First Affiliated Hospital of Zhengzhou University

研究负责人所在单位:

郑州大学第一附属医院

Affiliation of the Leader:

The First Affiliated Hospital of Zhengzhou University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2020-KY-283

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

郑州大学第一附属医院科研项目伦理审查委员会

Name of the ethic committee:

The First Affiliated Hospital of Zhengzhou University Research Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2020-07-31 00:00:00

伦理委员会联系人:

郑州大学第一附属医院科研项目伦理审查委员会

Contact Name of the ethic committee:

The First Affiliated Hospital of Zhengzhou University Research Ethics Committee

伦理委员会联系地址:

河南省郑州市二七区建设东路1号

Contact Address of the ethic committee:

1 Jianshe Road East, Zhengzhou, He'nan, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

郑州大学第一附属医院

Primary sponsor:

The First Affiliated Hospital of Zhengzhou University

研究实施负责(组长)单位地址:

河南省郑州市二七区建设东路1号

Primary sponsor's address:

1 Jianshe Road East, Erqi District, Zhengzhou, He'nan, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

河南省

市(区县):

郑州市

Country:

China

Province:

He'nan

City:

Zhengzhou

单位(医院):

郑州大学第一附属医院

具体地址:

河南省郑州市二七区建设东路1号

Institution
hospital:

The First Affiliated Hospital of Zhengzhou University

Address:

1 Jianshe Road East, Erqi District

经费或物资来源:

拟经费来自河南省科学技术厅

Source(s) of funding:

plan to acquire the funds from the Science and Technology Department of Henan Province

研究疾病:

新型冠状病毒肺炎(COVID-19)  

Target disease:

Novel Coronavirus Pneumonia (COVID-19)

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

1. 探讨新冠肺炎患者临床治疗后肺部高分辨CT、肺功能及抗体等的动态变化,以期全面了解被COVID-19损害的肺组织和其它脏器在近期及远期的恢复情况; 2. 采用圣乔治呼吸问卷(SGRQ)调查COVID-19恢复期患者身体健康状况,汉密尔顿焦虑与抑郁量表调查随访其心理健康状况,以期了解新冠肺炎患者近期及远期愈后身心状况。 3.本研究拟探讨现实生活中COVID-19患者的脏器功能及身心状况动态变化特点及可能的影响因素,对COVID-19防控、患者管理及个体化治疗提供理论依据。  

Objectives of Study:

1. Explore the COVID-19 patients'chest HRCT,pulmonary function,antibodies and so on after clinical treatment, and fully understand the recovery of lung tissues and other organs damaged by COVID-19 in the near and long term; 2. Use the SGRQ to investigate the convalescent health status of COVID-19 patients. Use the HAMA and the HAMD to investigate the convalescent psychologic status of COVID-19 patients.Fully understand the recovery of the health status and psychologic status in the near and long term; 3. This study plans to explore the covid-19 patients' organ function,physical and mental conditions in real life, and the possible influencing factors, so that we can provide the theoretical basis for covid-19 prevention, patients'management and individualized treatment.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

COVID-19患者排除标准:符合下列任一条者排除:①不符合纳入标准;②除COVID-19外,在过去2周之中还出现了其他重大的应激事件;③近期曾有精神类药物用药史。
对照组排除标准:不符合纳入标准。

Exclusion criteria:

The COVID-19 patients'exclusion criteria:
1. In addition to covid-19, other major stress events have occurred in the past two weeks;
2. Recently psychotropic drugs have been used.

研究实施时间:

Study execute time:

From 2020-02-01 00:00:00 To 2022-02-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-02-01 00:00:00 To 2020-05-02 00:00:00

干预措施:

Interventions:

组别:

COVID-19患者组

样本量:

58

Group:

COVID-19 patient group

Sample size:

干预措施:

干预措施代码:

Intervention:

Nil

Intervention code:

组别:

对照组

样本量:

58

Group:

control group

Sample size:

干预措施:

干预措施代码:

Intervention:

nothing

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

河南省 

市(区县):

郑州市 

Country:

China

Province:

He'nan

City:

单位(医院):

郑州大学第一附属医院 

单位级别:

三甲医院 

Institution
hospital:

The First Affiliated Hospital of Zhengzhou University

Level of the institution:

Tertiary A Hospital

国家:

中国

省(直辖市):

河南省 

市(区县):

信阳市 

Country:

China

Province:

He'nan

City:

单位(医院):

光山县人民医院 

单位级别:

二甲医院 

Institution
hospital:

Guangshan County People's Hospital

Level of the institution:

Secondary A Hospital

国家:

中国

省(直辖市):

河南省 

市(区县):

信阳市 

Country:

China

Province:

He'nan

City:

单位(医院):

息县人民医院 

单位级别:

二甲医院 

Institution
hospital:

Xixian People's Hospital

Level of the institution:

Secondary A Hospital

测量指标:

Outcomes:

指标中文名:

肺功能检测

指标类型:

主要指标

Outcome:

pulmonary function test

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

IgG及IgM抗体水平

指标类型:

主要指标

Outcome:

the antibodies level of IgG and IgM

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

圣乔治呼吸问卷

指标类型:

主要指标

Outcome:

St.George's Respiratory Questionnaire

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

汉密尔顿焦虑量表

指标类型:

主要指标

Outcome:

Hamilton Anxiety Scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

汉密尔顿抑郁量表

指标类型:

主要指标

Outcome:

Hamilton Depression Scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

nothing

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

N/A

Blinding:

N/A

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

研究完成后6个月内对原始数据进行公开,共享平台待定。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

We will make the raw data public within six months of the completion of the study, but the sharing platform remains to be determined

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

所有临床资料将会由郑州大学第一附属医院呼吸重症科的医护人员统一录入和核对,而数据库由许爱国及赵玉苗共同管理。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

All clinical data will be recorded and checked by medical workers from the respiratory department of the First Affiliated Hospital of Zhengzhou University, and the database will be jointly managed by Xu Aiguo and Zhao Yumiao.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2020-05-23 17:08:17